


Workshop Dissolution Testing

HMPs containing comminuted herbal drugs

GA Annual Meeting

Florence, 22 August 2005

Dr. Hartwig Sievers, PhytoLab




Problem

For a variety of herbal drugs, Commission E (and ESCOP) monographs refer under "dosage" to

"XYZ g of herbal drug; equivalent preparations"


This poses a problem where clinical data are available in the meantime for some preparations, mostly extracts, although a wide range of preparations has been used in the same tenor for a long time when the monograph was established.



Problem

Especially where the clinically undocumented preparation contains the comminuted drug doubts have been raised as to whether the relevant substances would sufficiently dissolve

_




BfArM/Commission E approach

- Where therapeutically active substances are known, dissolution of these substances from different products may be compared.
- Where therapeutically active substances are not known, comparison of the dissolution of suitable marker substances from the crude drug preparation with the respective infusion or approved/sufficiently documented extract preparation can be acceptable.

"Erläuterungen zum Antrag auf Zulassung eines Arzneimittels beim Bundesinstitut für Arzneimittel und Medizinprodukte", 3. Auflage, vom 31.10.1996 (BAnz. Nr. 44a vom 05.03.1997)"

. . .



Example 1 – Senna leaf

Commission E

Comminuted herb, powder or dried extracts for teas, decoctions, cold macerates, or elixirs.

20-30mg hydroxyanthracene derivatives daily, calculated as sennoside B

Product, Dosage

Senna Tea; 1.0-1.2g Senna leaf acc. to 30mg hydroxyanthracene derivatives calc. as sennoside B; Excipients (herbs) 0.4-0.6g

Proposed mode of administration


Infuse with cold or warm water for 20 min or administer directly with water


Are Sennosides sufficiently available from ingested leaf powder?



Example 1 – Senna leaf


Transition Rate of Sennosides into Senna leaf infusion






Example 1 – Senna leaf

Dissolution Profile of Sennosides from Senna leaf powder



time [min]



Example 2 – Ginseng root

Commission E

Unless otherwise prescribed (daily)

1-2g of root; equivalent preparations


ESCOP

Adult daily dose: 0.5-2g of dried root; equivalent preparations

Product, Dosage


Ginseng root capsules;
350mg Ginseng root powder


Are Ginsenosides sufficiently available from Powder Capsules?



Example 2 – Ginseng root







Example 3 - Lycopus europaeus, Bugleweed

Commission E


Dosage lies between a daily dose of 1-2g of drug for teas and water-ethanol extracts equivalent of 20mg of drug.

Note: Each patient has his own individual optimal level of thyroid hormone. Only rough estimation of dosage is possible for thyroid disorders, in which age and weight must be considered

Product, Dosage


1 Tablet contains
Lycopi europaei herba 20mg


Are tablets with powdered herb equivalent to extract tablets?



Example 3 – Lycopus europaeus, Bugleweed


Dissolution of Rosmarinic acid from Lycopus Extract and Powder Tablets





Conclusion

- In many cases secondary substances are at least equally soluble from the herbal matrix under simulated intestinal condiions as compared to extracts or a hot water infusion
- ➤ The extent and speed of dissolution from herbal matrices depends on particle size. Particle size must therefore be adequately specified and controlled.



Conclusion

- ➤ The examples show that administration of comminuted herbs may be reasonable in many cases.
- ➤ demonstration of high dissolution rates (>80%/45min) from the herbal matrix of therapeutically active substances should be acknowledged in WEU applications of herbal products with no sufficient direct clinical evidence.
- ➤ demonstration of high dissolution rates (>80%/45min) from the herbal matrix of of markers assumedly contributing to efficay may be suitable to add plausibility for the claimed indication in THMP procedures where other preparations of the same herbal drug are approved on WEU level.

II. O'r and

